Perhaps it's the sweet California air, but the pervasive (though not universal) pessimism in biopharma these days is really bumming me out.  Consequently, I'd like to discuss three potential responses to difficult industry problems.

AEI health care policy expert Thomas (Tom) Miller explains why current Medicare reform proposals are mostly "policy concepts devoid of structural details." Miller points out that even the Ryan-Wyden proposal which "makes an honest effort to start this process at the ‘high-concept’ level,” needs “a more detailed script that begins to answer at least 13 more questions."

Despite an unbroken record of failed efforts to usher in a utopian “green” economy, proponents of the great green future are undaunted.

India is on the brink of finalizing a free trade agreement with the European Union. Yet even as the deal gets close, one area remains hotly contested: protection for intellectual property (IP). Controversy mounts over "data exclusivity" for pharmaceuticals.

Obama can follow the long tradition of U.S. presidents who turned from frustration at home to success abroad by resolving to conclude the World Trade Organization's Doha Round of global talks next year.

By wide margins, Americans want our elected officials to work together. But Democrats and independents want compromise while Republicans want their politicians to stick to principle.

This Outlook describes the sad, and largely unsuccessful, history of UN reform efforts in the past thirty years and proposes a revolutionary change that might actually produce a different result: moving toward voluntary funding of the UN and its activities.

This study attempts to ascertain whether registered medicines perform better in simple quality tests than those that are either not registered or not known to be registered.